• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Talis Biomedical Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    9/17/24 4:11:46 PM ET
    $TLIS
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $TLIS alert in real time by email
    8-K
    False000158475100015847512024-09-162024-09-16

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): September 17, 2024 (September 16, 2024)

     

     

    Talis Biomedical Corporation

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-40047

    46-3122255

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    1375 West Fulton Market

    Suite 700

     

    Chicago, Illinois

     

    60607

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (650) 433-3000

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐

     

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

     

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

     

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

     

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.0001 par value per share

     

    TLIS

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     


     

    Item 1.01. Entry into a Material Definitive Agreement.

    On September 16, 2024, the Company entered into an agreement (the “Lease Termination Agreement”) with Fulton Ogden Venture, LLC (the “Landlord”) to terminate the Company’s lease for its Chicago office located at 1375 West Fulton Market, Suite 700, Chicago, Illinois, 60707 (the “Original Lease Agreement”). In order to terminate the Original Lease Agreement, the Company paid the Landlord a total fee of $3,621,703.94, which included a termination fee equal to $3,404,526.80 and a prepayment of the rent and operating costs for the month of October 2024 of $217,177.14. As modified by the terms of the Lease Termination Agreement, the lease will expire on October 31, 2024.

    As previously disclosed in the periodic reports that the Company files with the SEC, the Company is required to hold a letter of credit (“LOC”) in the amount of $766,528.00 to secure the Original Lease Agreement through its expiration. Upon expiration of the Original Lease Agreement on October 31, 2024, and if the Company is not then in default under the Original Lease Agreement, the Landlord shall return the letter of credit and any unused cash proceeds from a draw on the letter of credit to the Company within 10 business days after fulfillment by the Company of all its obligations under the Lease Termination Agreement.

     

    The foregoing description of the Original Lease Agreement and the Lease Termination Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Original Lease Agreement and the Lease Termination Agreement and the exhibits thereto, copies of which are attached hereto as Exhibit 10.1 and Exhibit 10.2 and are incorporated herein by reference.

     

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

    Exhibit Number

    Description

    10.1

    Lease Termination Agreement dated September 16, 2024 entered into between Talis Biomedical Corporation and Fulton Ogden Venture, LLC.

    10.2

    Lease, dated January 20, 2021, by and between Talis Biomedical Corporation and Fulton Ogden Venture, LLC (incorporated by reference to Exhibit 10.2 to the Company’s Registration Statement on Form S-1 (File No. 333-252360), filed with the SEC on February 8, 2021).

    104

    Cover Page Interactive Data File (Embedded within the Inline XBRL document)

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    Talis Biomedical Corporation

     

     

     

     

    Date:

    September 17, 2024

    By:

    /s/ Robert J. Kelley

     

     

     

    Robert J. Kelley
    Chief Executive Officer

     

     


    Get the next $TLIS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TLIS

    DatePrice TargetRatingAnalyst
    1/7/2022$3.00Neutral → Underperform
    BofA Securities
    9/27/2021$10.00 → $7.00Neutral → Underweight
    JP Morgan
    8/31/2021Buy → Neutral
    BTIG Research
    8/12/2021$9.00Overweight → Neutral
    Piper Sandler
    8/11/2021$17.00 → $10.00Overweight → Neutral
    JP Morgan
    More analyst ratings

    $TLIS
    Leadership Updates

    Live Leadership Updates

    See more
    • Talis Biomedical Announces Andrew Lukowiak, Ph.D., as President and Chief Scientific Officer (CSO)

      REDWOOD CITY, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care (POC), today announced that it has appointed Dr. Andrew A. Lukowiak as president and chief scientific officer, effective August 1, 2023. Dr. Lukowiak has more than 20 years of senior leadership experience in the clinical diagnostics industry at both publicly traded and privately held commercial-stage companies. As a member of the executive leadership team, he will be responsible for leading the assay development, platf

      8/2/23 8:00:00 AM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Talis Biomedical Appoints Former Roche Molecular CEO Heiner Dreismann to Board of Directors, Announces Former Genomic Health CEO Kim Popovits as Lead Independent Director

      REDWOOD CITY, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced Heiner Dreismann has joined its board of directors, effective immediately. Talis Bio also recently appointed Kim Popovits, who has served as a member of the board since March 2020, as its lead independent director. "Heiner's entrepreneurial vision and track record leading multiple corporate functions over the course of his 20-year tenure at Roche Diagnostics are ideal for the opportunities Talis Bio is

      5/23/23 8:00:00 AM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Talis Biomedical Announces Leadership Transition

      MENLO PARK, Calif., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that Rob Kelley, the Company's current Chief Commercial Officer, has been promoted to Chief Executive Officer and Director, effective immediately. Brian Blaser has stepped down from the positions of President, Chief Executive Officer and Director, due to personal matters. About Rob KelleyMr. Kelley has more than 25 years of leadership experience in the biotechnology industry and has served as the Company's Chief Co

      12/8/21 8:00:00 AM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TLIS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Leonard Braden Michael bought $44,240 worth of shares (30,100 units at $1.47) (SEC Form 4)

      4 - Talis Biomedical Corp (0001584751) (Issuer)

      9/9/24 4:24:12 PM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Large owner Leonard Braden Michael bought $2,000 worth of shares (500 units at $4.00) (SEC Form 4)

      4 - Talis Biomedical Corp (0001584751) (Issuer)

      9/5/24 11:57:28 AM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Large owner Leonard Braden Michael bought $642 worth of shares (151 units at $4.25) (SEC Form 4)

      4 - Talis Biomedical Corp (0001584751) (Issuer)

      9/4/24 8:19:50 PM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TLIS
    SEC Filings

    See more
    • SEC Form 15-12G filed by Talis Biomedical Corporation

      15-12G - Talis Biomedical Corp (0001584751) (Filer)

      9/30/24 6:05:56 AM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 25-NSE filed by Talis Biomedical Corporation

      25-NSE - Talis Biomedical Corp (0001584751) (Subject)

      9/20/24 8:57:32 AM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Talis Biomedical Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Talis Biomedical Corp (0001584751) (Filer)

      9/17/24 4:11:46 PM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TLIS
    Financials

    Live finance-specific insights

    See more
    • Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve Cash

      REDWOOD CITY, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced it has initiated a process to explore strategic alternatives with the goal of maximizing shareholder value. While the Company has made progress developing the Talis One® system, it believes that this is a prudent path forward given current market conditions. As part of this process, the Company's Board of Directors has appointed a special committee of independent, disinterested directors to consider a

      11/14/23 8:00:00 AM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Talis Biomedical to Report Second Quarter 2023 Financial Results and Provide a Business Update on August 10, 2023

      REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will report second quarter 2023 financial results and provide a business update on Thursday, August 10, 2023, after market close. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). The live webcast of the event may be accessed by registering online for dial-in information via the News & Events page of the investor section o

      8/3/23 8:00:00 AM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Talis Biomedical to Provide Business Update and Financial Results on May 11, 2023

      REDWOOD CITY, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will provide a business update and financial results on Thursday, May 11, 2023, after market close. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). The live webcast of the event may be accessed by registering online for dial-in information via the News & Events page of the investor section of Talis Biomedical's w

      5/4/23 8:00:00 AM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TLIS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Leonard Braden Michael bought $44,240 worth of shares (30,100 units at $1.47) (SEC Form 4)

      4 - Talis Biomedical Corp (0001584751) (Issuer)

      9/9/24 4:24:12 PM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Large owner Leonard Braden Michael bought $2,000 worth of shares (500 units at $4.00) (SEC Form 4)

      4 - Talis Biomedical Corp (0001584751) (Issuer)

      9/5/24 11:57:28 AM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Large owner Leonard Braden Michael bought $642 worth of shares (151 units at $4.25) (SEC Form 4)

      4 - Talis Biomedical Corp (0001584751) (Issuer)

      9/4/24 8:19:50 PM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TLIS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve Cash

      REDWOOD CITY, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced it has initiated a process to explore strategic alternatives with the goal of maximizing shareholder value. While the Company has made progress developing the Talis One® system, it believes that this is a prudent path forward given current market conditions. As part of this process, the Company's Board of Directors has appointed a special committee of independent, disinterested directors to consider a

      11/14/23 8:00:00 AM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Talis Biomedical Announces Second Quarter 2023 Financial Results and Business Update

      REDWOOD CITY, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today reported financial results for the second quarter ended June 30, 2023, and provided a business update. Recent Business Highlights Initiated clinical study to support COVID-19 510(k) submission for clearance of the Talis One® systemPresented positive data at the Infectious Disease Society for Obstetrics and Gynecology (IDSOG) annual meeting differentiating the planned Talis One test menu Development-stage chlamy

      8/10/23 4:05:00 PM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Talis Biomedical to Report Second Quarter 2023 Financial Results and Provide a Business Update on August 10, 2023

      REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will report second quarter 2023 financial results and provide a business update on Thursday, August 10, 2023, after market close. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). The live webcast of the event may be accessed by registering online for dial-in information via the News & Events page of the investor section o

      8/3/23 8:00:00 AM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TLIS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Talis Biomedical Corporation

      SC 13D/A - Talis Biomedical Corp (0001584751) (Subject)

      10/10/24 5:01:39 PM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Talis Biomedical Corporation

      SC 13G/A - Talis Biomedical Corp (0001584751) (Subject)

      8/14/24 9:23:03 PM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Talis Biomedical Corporation

      SC 13G - Talis Biomedical Corp (0001584751) (Subject)

      8/14/24 8:44:42 PM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TLIS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Talis Biomedical downgraded by BofA Securities with a new price target

      BofA Securities downgraded Talis Biomedical from Neutral to Underperform and set a new price target of $3.00

      1/7/22 8:55:21 AM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Talis Biomedical downgraded by JP Morgan with a new price target

      JP Morgan downgraded Talis Biomedical from Neutral to Underweight and set a new price target of $7.00 from $10.00 previously

      9/27/21 5:04:24 AM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Talis Biomedical downgraded by BTIG Research

      BTIG Research downgraded Talis Biomedical from Buy to Neutral

      8/31/21 3:31:48 PM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials